Regulatory Neuropeptides & Cognition: A Research Literature Overview

NOVA Q Research · Research Library

Regulatory Neuropeptides & Cognition: A Research Literature Overview

What the published research examines for Semax — an ACTH(4-10)-derived heptapeptide — and the surrounding neuropeptide research landscape (Selank, BDNF/TrkB signaling).

Neutral literature aggregation · Compiled by NOVA Q Research · Updated 2026-07-24 · 8 cited sources
In brief
  • Semax is a synthetic ACTH(4-7) heptapeptide extended with Pro-Gly-Pro; it is registered in Russia but not approved in the US/EU/UK.
  • Most mechanistic data are rodent and in-vitro, focused on BDNF/TrkB expression, monoaminergic systems, and ischemia gene-expression changes.
  • Clinical reports (e.g. acute ischemic stroke) are largely from Russian centers and Russian-language journals, limiting independent appraisal.
  • Related compounds (Selank) and BDNF-linked mechanisms are included as landscape context, not as products.

Regulatory peptides derived from ACTH and the broader melanocortin family have been studied as short-chain modulators of central-nervous-system signaling, with interest in ACTH(4–10) fragments that lack corticotropic activity but retain reported neuronal effects. A recurring theme is modulation of BDNF/TrkB neurotrophic signaling. Semax, the most-studied compound in this niche, is registered as a pharmaceutical in Russia for neurological indications and holds no equivalent approval in the US, EU, or UK. Because its development is concentrated in Russian groups, interpreting the evidence requires attention to replication and language of publication.

Semax

Class / mechanism. A synthetic peptide (Met-Glu-His-Phe-Pro-Gly-Pro) corresponding to the ACTH(4-7) fragment extended with a Pro-Gly-Pro terminus for enzymatic stability; devoid of the adrenal-stimulating activity of full-length ACTH. Reported mechanisms center on BDNF/TrkB modulation, monoaminergic effects, and ischemia-related gene expression.

Published work on Semax spans in-vitro cell and tissue models, rodent behavioral and biochemical studies, and clinical reports from Russian centers, predominantly in cerebrovascular and cognitive-neurology contexts. A substantial preclinical body examines whether Semax alters neurotrophin (BDNF/TrkB) expression in the hippocampus and basal forebrain; a second strand uses rodent cerebral-ischemia models to examine genome- and protein-level expression changes.

N-acetyl Semax and the N-acetyl Semax amidate are structural modifications discussed in the peptide-chemistry literature; peer-reviewed pharmacological characterization of these specific analogs is more limited than for Semax itself, and they are best understood as related research chemicals.

Selected literature

  1. Dolotov OV, et al. 2006. “Semax regulates BDNF and trkB expression in the rat hippocampus.” Brain Res 1117(1):54–60. PMID 16996037. https://pubmed.ncbi.nlm.nih.gov/16996037/Rodent study of Semax-associated BDNF and TrkB expression in the hippocampus.
  2. Dolotov OV, et al. 2006. “Semax binds specifically and increases BDNF protein in rat basal forebrain.” J Neurochem 97(1):82–86. PMID 16635254. https://pubmed.ncbi.nlm.nih.gov/16635254/Specific-binding and BDNF-protein study in rat basal forebrain.
  3. Medvedeva EV, et al. 2014. “Semax affects immune- and vascular-system gene expression in rat brain focal ischemia.” BMC Genomics 15:228. PMID 24661604. https://pubmed.ncbi.nlm.nih.gov/24661604/Genome-wide transcriptional analysis in a rat focal-ischemia model.
  4. Gusev EI, et al. 1997. “Effectiveness of semax in the acute period of hemispheric ischemic stroke.” Zh Nevrol Psikhiatr. PMID 11517472. https://pubmed.ncbi.nlm.nih.gov/11517472/Russian-language clinical and electrophysiological report in acute ischemic stroke.
  5. Eremin KO, et al. 2005. “Semax activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res 30(12):1493–1500. PMID 16362768. https://pubmed.ncbi.nlm.nih.gov/16362768/Rodent study of neurotransmitter-system activation.
Where the evidence is limited. The evidence base is heavily concentrated in a small number of Russian groups, and several foundational reports are in Russian-language journals, limiting independent international replication. Much mechanistic data is rodent/in-vitro; large-scale blinded Western-replicated clinical research is limited, and mechanistic hypotheses (e.g. BDNF/TrkB) remain active investigation rather than settled conclusions.

Related research landscape (context, not products)

Class / mechanism. Included solely to characterize the surrounding regulatory-neuropeptide research area. These compounds are not part of the catalog.

Selank, a synthetic heptapeptide analog of the endogenous immunopeptide tuftsin, was developed by the same research lineage associated with Semax and is frequently studied alongside it. Its literature emphasizes anxiolytic-related pharmacology, GABAergic gene-expression effects, and — paralleling Semax — BDNF modulation in rodent brain. As with Semax, much clinical work is Russian in origin and Selank holds no US/EU/UK marketing authorization.

More broadly, review-level literature situates ACTH(4–10)-derived and melanocortin peptides within neuroprotective-peptide drug-discovery efforts, treating BDNF/TrkB neurotrophic signaling as a shared candidate mechanism.

Selected literature

  1. Inozemtseva LS, et al. 2008. “Intranasal Selank regulates BDNF expression in the rat hippocampus in vivo.” Dokl Biol Sci 421:241–243. PMID 18841804. https://pubmed.ncbi.nlm.nih.gov/18841804/Rodent study of intranasal Selank and hippocampal BDNF expression.
  2. Kolik LG, et al. 2019. “Selank protects against ethanol-induced memory impairment by regulating BDNF in rats.” Bull Exp Biol Med 167(5):641–644. PMID 31625062. https://pubmed.ncbi.nlm.nih.gov/31625062/Rodent study of Selank and BDNF in a memory-impairment model.
  3. Dergunova LV, et al. 2023. “Neuroprotective peptides and new strategies for ischemic-stroke drug discovery.” Genes 14(5):953. PMID 37239313. https://pubmed.ncbi.nlm.nih.gov/37239313/Review of neuroprotective-peptide research providing landscape context.
Where the evidence is limited. Landscape context only; these compounds are not products and are presented to situate the research area.

How to read this report

This report aggregates published scientific literature for the compounds NOVA Q Research supplies in the Cognitive category. It describes what studies investigated, the models used, and the maturity of the evidence. It does not evaluate, recommend, or imply any use in humans or animals, and it is not medical, veterinary, or research-protocol advice. Where the record is preclinical or geographically concentrated, we say so. Every source is cited so it can be checked independently.

Browse the Cognitive catalog →
For research use only. Not for human or veterinary use. NOVA Q Research supplies research-grade materials for laboratory research use only. Nothing in this document is intended to diagnose, treat, cure, or prevent any disease, or to guide human or veterinary use. Statements have not been evaluated by the FDA. Citations are provided for reference and do not imply endorsement.